Clinical trial
TroVax Renal Immunotherapy Survival Trial
NCT00397345 · Oxford BioMedica, Industry · Completed
Key facts
| NCT number | NCT00397345 |
|---|---|
| Title | TroVax Renal Immunotherapy Survival Trial |
| Official title | Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma. |
| Lead sponsor | Oxford BioMedica, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Carcinoma |
| Intervention type | Biological |
| Interventions | Trovax, Placebo, Standard of care therapy |
| Enrollment | 733 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Nov 9, 2006 |
| Last update posted | Oct 19, 2020 |
| Countries | France, Germany, Israel, Poland, Romania, Russia, Spain, Ukraine, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: